ClinicalTrials.gg
RecruitingNCT07419399RDPPUpdated Jun 25, 2026

Acute Effects of Radiofrequency Diathermy in Postpartum Women With Diastasis Abdominis

An interventional study of Radiofrequency diathermy (RFD) and Radiofrequency diathermy (RFD) in Postpartum and Rectus Muscle Diastasis, sponsored by University of Valencia. Recruiting at 1 site in Spain. Open to female participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-25.

Sponsored by University of Valencia · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
Female
01

Study summary

This clinical trial aims to compare the immediate tissue response in postpartum women with and without rectus abdominis diastasis (RAD) after undergoing radiofrequency diathermy (RFD) treatment. The main question it seeks to answer is: Do postpartum women with and without RAD exhibit different acute tissue responses in terms of pressure pain threshold, superficial thermal sensitivity, and tissue elasticity? To determine whether there are differences in these acute tissue responses between the groups, researchers will compare RFD with a sham RFD intervention in postpartum women with and without RAD.

Participants will receive one session of either RFD or a sham RFD intervention and will complete three assessments: one at baseline and two after the intervention, one immediately afterwards and one 20 minutes afterwards.

Read the detailed description

A randomised controlled experimental study will be conducted. The sample will consist of 48 postpartum women: 24 who have been diagnosed with pathological RAD and 24 who have not. The participants will be randomly assigned to one of two groups: (i) a radiofrequency diathermy (RFD) group (n = 12), and (ii) a sham RFD group (n = 12). All participants will receive a single treatment session. Evaluations will be performed at three time points: baseline, immediately after the intervention and 20 minutes post-intervention. The variables assessed will include pressure pain threshold, superficial thermal sensitivity and tissue elasticity.

02

Conditions studied

  • Postpartum
  • Rectus Muscle Diastasis

Browse trials for

Keywords

  • rectus abdominis diastasis
  • radiofrequency diathermy
  • postpartum
03

In context

Diastasis, Muscle

7 studies on the registry are indexed under Diastasis, Muscle; 3 are open to participants now.

Browse Diastasis, Muscle studies →

Lead sponsor

University of Valencia is the lead sponsor of 357 studies on the registry; 75 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 20 and 45 years old.
  • between 18.5 and 29.9 kg/mw.
  • Postpartum period between 6 months and 1 year Additionally, in the group of women with RAD, pathological RAD will be defined as an inter-rectus distance greater than 2.2 cm (measured 3 cm above the navel), according to the criteria of Beer et al. (2009)

Exclusion criteria

Exclusion Criteria:

  • Previous surgeries involving the abdominal wall.
  • Cesarean deliveries.
  • Women diagnosed with chronic pain
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    RFD women with RAD

    Women with RAD will receive RFD for 20 minutes, with 10 minutes applied using the capacitive method and 10 minutes using the resistive method.

    Other: Radiofrequency diathermy (RFD)

  • Experimental
    RFD women without RAD

    Women without RAD will also receive RFD for 20 minutes, with 10 minutes applied using the capacitive method and 10 minutes using the resistive method

    Other: Radiofrequency diathermy (RFD)

  • Sham comparator
    Sham RFD women with RAD

    Women with RAD will receive 20 minutes of application of the RFD device without energy emission. 10 minutes using the capacitive electrode and 10 minutes using the resistive electrode.

    Other: Sham radiofrequency diathermy ( sham RFD)

  • Sham comparator
    Sham RFD women without RAD

    Women without RAD will likewise receive 20 minutes of application of the RFD device without energy emission. 10 minutes using the capacitive electrode and 10 minutes using the resistive electrode.

    Other: Sham radiofrequency diathermy ( sham RFD)

Interventions

  • OtherRadiofrequency diathermy (RFD)

    RFD for 20 minutes, with 10 minutes applied using the capacitive method and 10 minutes using the resistive method.

    Also known as: Radiofrequency, Diathermy

  • OtherRadiofrequency diathermy (RFD)

    RFD for 20 minutes, with 10 minutes applied using the capacitive method and 10 minutes using the resistive method

    Also known as: Radiofrequency, Diathermy

  • OtherSham radiofrequency diathermy ( sham RFD)

    20 minutes of application of the RFD device without energy emission. 10 minutes using the capacitative electrode, and 10 minutes using the resistive electrode.

  • OtherSham radiofrequency diathermy ( sham RFD)

    20 minutes of application of the RFD device without energy emission.10 minutes using the capacitative electrode, and 10 minutes using the resistive electrode.

06

What researchers measure

Primary outcomes

  1. Pressure pain threshold

    The pressure pain threshold will be measured using an algometer by applying progressive force to a supraumbilical point (three centimetres above the navel, at the lateral border of the rectus abdominis on the dominant side) until the participant reports pain. A higher value indicates a higher pain threshold.

    Time frame: Baseline, immediately after the intervention and 20 minutes after the intervention.

  2. Superficial thermal sensitivity

    Superficial thermal sensitivity will be assessed using the Thermal Visual Analogue Scale. For this, the capacitive electrode will be placed over the rectus abdominis on both sides for 30 seconds. Participants will then rate their thermal sensation on a scale from 0 (no heat) to 10 (maximum tolerable heat).

    Time frame: Baseline, immediately after the interventino and 20 minutes after the intervention

  3. Tissue elasticity

    The MyotonPRO® myometer will be used to measure tissue elasticity over the rectus abdominis on both sides. Higher values indicate greater stiffness and lower tissue elasticity.

    Time frame: Baseline, immediately after the interventino and 20 minutes after the intervention

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Beer GM, Schuster A, Seifert B, Manestar M, Mihic-Probst D, Weber SA. The normal width of the linea alba in nulliparous women. Clin Anat. 2009 Sep;22(6):706-11. doi: 10.1002/ca.20836. PubMed 19637295 ↗
  • Clijsen R, Leoni D, Schneebeli A, Cescon C, Soldini E, Li L, Barbero M. Does the Application of Tecar Therapy Affect Temperature and Perfusion of Skin and Muscle Microcirculation? A Pilot Feasibility Study on Healthy Subjects. J Altern Complement Med. 2020 Feb;26(2):147-153. doi: 10.1089/acm.2019.0165. Epub 2019 Oct 3. PubMed 31580698 ↗
  • Fuentes-Aparicio L, Munoz-Gomez E, Molla-Casanova S, Moreno-Segura N, Ingles M. Impact of capacitive resistive monopolar radiofrequency prior to a therapeutic physical exercise program on morphology and functionality in women with rectus diastasis: a randomized controlled trial. Disabil Rehabil. 2026 Jan;48(2):470-481. doi: 10.1080/09638288.2025.2540068. Epub 2025 Jul 31. PubMed 40740146 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Mar 2029, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2026
First posted
Feb 19, 2026
StartActual
Mar 30, 2026
Primary completionEst.
Mar 30, 2029
CompletionEst.
Mar 30, 2029
Last update
Jun 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07419399
Responsible party
Marta Inglés de la Torre (Dr, University of Valencia) — Principal investigator
First posted
Feb 19, 2026
Start date
Mar 30, 2026
Primary completion
Mar 30, 2029 (estimated)
Completion
Mar 30, 2029 (estimated)
Last update
Jun 25, 2026

Study contacts

Marta Inglés de la Torre, PHD
Contact
marta.ingles@uv.es
686320380

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion